Short Interest in CollPlant Biotechnologies Ltd. (NASDAQ:CLGN) Rises By 24.8%

CollPlant Biotechnologies Ltd. (NASDAQ:CLGNGet Rating) saw a large growth in short interest in the month of March. As of March 31st, there was short interest totalling 127,700 shares, a growth of 24.8% from the March 15th total of 102,300 shares. Approximately 1.7% of the shares of the company are sold short. Based on an average trading volume of 51,000 shares, the short-interest ratio is currently 2.5 days.

Separately, Zacks Investment Research cut shares of CollPlant Biotechnologies from a “hold” rating to a “strong sell” rating in a research note on Tuesday, April 12th.

Shares of NASDAQ CLGN opened at $9.74 on Tuesday. CollPlant Biotechnologies has a 52 week low of $8.60 and a 52 week high of $23.49. The firm has a 50-day moving average price of $10.63 and a 200 day moving average price of $14.02. The stock has a market capitalization of $55.23 million and a price-to-earnings ratio of -973.03.

CollPlant Biotechnologies (NASDAQ:CLGNGet Rating) last issued its quarterly earnings results on Thursday, March 24th. The company reported ($0.30) EPS for the quarter, missing analysts’ consensus estimates of ($0.26) by ($0.04). CollPlant Biotechnologies had a return on equity of 0.49% and a net margin of 1.52%. The firm had revenue of $0.31 million for the quarter. Research analysts forecast that CollPlant Biotechnologies will post -0.38 earnings per share for the current fiscal year.

A number of institutional investors have recently added to or reduced their stakes in CLGN. Renaissance Technologies LLC purchased a new stake in CollPlant Biotechnologies in the third quarter valued at approximately $169,000. Susquehanna International Group LLP acquired a new position in CollPlant Biotechnologies during the fourth quarter valued at approximately $173,000. LPL Financial LLC acquired a new position in CollPlant Biotechnologies during the fourth quarter valued at approximately $242,000. Citadel Advisors LLC acquired a new position in CollPlant Biotechnologies during the second quarter valued at approximately $276,000. Finally, Kingsview Wealth Management LLC acquired a new position in CollPlant Biotechnologies during the fourth quarter valued at approximately $301,000.

About CollPlant Biotechnologies (Get Rating)

CollPlant Biotechnologies Ltd., a regenerative and aesthetic medicine company, focuses on three-dimensional (3D) bioprinting of tissues and organs, and medical aesthetics in the United States, Canada, and Europe. Its products are based on recombinant type I human collagen that is produced with its proprietary plant based genetic engineering technology.

Read More

Receive News & Ratings for CollPlant Biotechnologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CollPlant Biotechnologies and related companies with MarketBeat.com's FREE daily email newsletter.